CT186 / 14 - A first-in-human phase 1 dose-escalation and expansion study of intratumoral oncolytic reovirus (RC402) as a monotherapy or in combination with pembrolizumab in advanced solid tumors,
This trial is due to present at the AACR 24 in the same segment as CF33- NHIS, it's been around a while and very much a competitor,
also of interest when you look up the presentation about CF33 no Yuman or Chong on the list. P Woodard and J Byon seem the senior ones.
Clinical trial abstracts are under embargo and will be released at 3:00 PM ET on Friday, April 5.
CT186 / 14 - A first-in-human phase 1 dose-escalation and...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
-0.002(3.28%) |
Mkt cap ! $431.8M | |||
| Open | High | Low | Value | Volume |
| 6.2¢ | 6.4¢ | 5.9¢ | $919.2K | 15.26M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 899777 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 110472 | 3 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.9¢ |
Change
-0.002 ( 4.53 %) |
||||
| Open | High | Low | Volume | ||
| 6.2¢ | 6.4¢ | 5.9¢ | 5930301 | ||
| Last updated 15.58pm 06/06/2024 ? | |||||
| IMU (ASX) Chart |